Interpretation of BARDA’s Priorities for 2023: Preparedness for the Next Pandemic Threat
Access the recording
Access the presentation
Note: CPE credit is not available
Contact
Stacey Lesanto
Technical Support
+1 844-580-6963BDO Employees
+1 844-580-6963Share
Contact
Stacey Lesanto
Technical Support
+1 844-580-6963BDO Employees
+1 844-580-6963Share
Related Events & Webcasts
Recording
Planning for a Return to Work: Considerations and Implications for the Life Sciences Industry
As the COVID-19 pandemic progresses, many executives are starting to rationalize how their teams safely return to work. With restrictions varying between regions and countries, it can be difficult to develop a comprehensive strategy. This challenge is further compounded by economic uncertainty and supplier dependencies.
Recording
2020 BDO Biotech Briefing
BDO’s annual Biotech Briefing examines the most recent 10-K SEC filings of companies listed on the NASDAQ Biotechnology Index. Join us as we analyze this year's findings and trends in the marketplace
Recording
Life Sciences and the Technical/GxP Virtual Audit – The Show Must Go On
In the face of COVID-19, the mission becomes even more critical. Innovation such as finding a way to continue to work without interruption due to CDC protocols, such as social distancing and travel bans, is imperative. Thanks to leveraging technology, we have made it possible to perform audits from a remote location, a method known as the “virtual audit”.
Recording
Federal Government Funding Opportunities for the Life Sciences Industry
The federal government has prioritized R&D for Covid-19 response efforts and will continue to do so until the health threat has been addressed. As these countermeasures are developed and deployed, the federal government’s biodefense R&D resources will be re-prioritized to address chemical, biological, radiological and nuclear threats, influenza and other emerging infectious diseases.
Recording
What’s Next for SPACs in the Life Sciences Industry? A Discussion with Ginkgo Bioworks
With over 200 SPAC and IPO’s over the last year, SPACs are hotter than ever. US stocks continue to be unpredictable, finding the right opening to debut on Wall Street can be tricky and costly. But are SPAC’s the right approach for most Life Sciences companies seeking capital.
Recording
The Evolving Federal Funding Landscape and Business Implications for the Life Sciences Industry
As Federal Government Agencies tasked with biodefense and public health continue response efforts to the acute phase of the COVID-19 pandemic, each Agency continues to balance strategic legacy initiatives and new fiscal year priorities.
Recording
HIPAA Privacy and Security: Recent Trends in Regulation, Enforcement, and Risk Management
Join this first webinar of BDO’s Healthcare and Life Sciences Data Protection Webinar Series to learn more about how organizations can address their efficiency, risk, and governance challenges by aligning approaches and functions to optimize compliance and leverage available protections.
Recording
Health Apps and HIPAA Business Associates’ Rising Obligations in Privacy and Health Data
Join our second webcast of BDO’s Healthcare and Life Sciences Data Protection Webinar Series to learn more about how organizations can address their efficiency, risk, and governance challenges by aligning approaches and functions to optimize compliance and leverage available protections.
Recording
Privacy and Website Compliance - Cookies, Consent, Tracking, Oh My!
Join the final webcast of BDO’s Healthcare and Life Sciences Data Protection Webinar Series to learn more about how organizations can address their efficiency, risk, and governance challenges by aligning approaches and functions to optimize compliance and leverage available protections.
Webcast
What Life Sciences CFOs Need to Know in 2023
According to the 2023 BDO Life Sciences CFO Outlook Survey, the life sciences industry is evolving from its pandemic gold-rush years. While 2022 revenues were quite strong, companies are facing increasing pressure to manage cash and meet investor expectations.